Pandion Therapeutics to Present at SVB Leerink 9th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pandion Therapeutics, a privately-held biotechnology company developing modular protein therapeutics for autoimmune disease, today announced that company management will present at the SVB Leerink 9th Annual Global Healthcare Conference on Tuesday, February 25, 2020 at 1:30 p.m. ET in New York, NY.
Pandion Therapeutics is developing modular biologics for autoimmune regulation that are designed to achieve lasting therapeutic outcomes for patients with autoimmune and inflammatory diseases. The company is developing its lead drug candidate, PT101, an IL-2 mutein Fc fusion protein that preferentially expands regulatory T cells, as well as a robust pipeline of systemic immune modulators and tissue-targeted therapeutics focused on the gut, liver, skin, kidneys, and pancreas. Pandion’s approach to developing modular proteins, antibodies and bispecifics includes two key elements: first, the innovative biologics are based on cutting-edge immunomodulators such as an IL-2 mutein or PD-1 agonist that work systemically by activating regulatory pathways of the immune system that suppress uncontrolled autoimmune responses; and second, these immunomodulators can be combined with tissue-selective tethers, building modular proteins and antibodies that target the precise location within the organ to deliver the desired effect. Pandion is backed by leading life sciences investors including Polaris Partners, Versant Ventures, Roche Venture Fund, SR One, BioInnovation Capital, and the JDRF T1D Fund. The company is headquartered in Cambridge, Massachusetts. Please visit www.pandiontx.com.
The Yates Network
Investor Relations Contact:
Stern Investor Relations, Inc.